Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy

Background: [(177)Lu]-PSMA-617 (Lu-PSMA) therapy is a promising therapeutic option for end-stage prostate cancer patients. Early treatment response at the first restaging after two therapy cycles might correlate with high treatment efficacy and long overall survival (OS). Therefore, the aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Seifert, Robert, Kessel, Katharina, Schlack, Katrin, Weckesser, Matthias, Kersting, David, Seitzer, Konstantin E., Weber, Manuel, Bögemann, Martin, Rahbar, Kambiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344008/
https://www.ncbi.nlm.nih.gov/pubmed/34373733
http://dx.doi.org/10.7150/thno.60222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344008/
https://www.ncbi.nlm.nih.gov/pubmed/34373733
http://dx.doi.org/10.7150/thno.60222

Ejemplares similares